FDA Approves DATROWAY — Daiichi Sankyo Inc.

# FDA Approves Daiichi Sankyo's DATROWAY (datopotamab deruxtecan) for Oncology Treatment Daiichi Sankyo Inc. received FDA approval for DATROWAY (datopotamab deruxtecan), an intravenous therapeutic agent that expands the Japanese pharmaceutical company's oncology portfolio and positions it to compete in the targeted cancer treatment market. The approval of this antibody-drug conjugate could drive significant revenue growth for Daiichi Sankyo and strengthen its presence in precision medicine, particularly among patients with specific tumor types amenable to this